For: | Digklia A, Voutsadakis IA. Targeted treatments for metastatic esophageal squamous cell cancer. World J Gastrointest Oncol 2013; 5(5): 88-96 [PMID: 23799158 DOI: 10.4251/wjgo.v5.i5.88] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v5/i5/88.htm |
Number | Citing Articles |
1 |
Natasha Garg, Constance Stoehr, Yan Shi Zhao, Heather Rojas, Chung-Tsen Hsueh. Metastatic squamous cell carcinoma of colon from esophageal cancer. Experimental Hematology & Oncology 2017; 6(1) doi: 10.1186/s40164-017-0069-2
|
2 |
Min-Shu Hsieh, Pei-Wen Yang, Li-Fan Wong, Jang-Ming Lee. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma. Oncotarget 2016; 7(24): 36956 doi: 10.18632/oncotarget.9231
|
3 |
Ka On Lam, Wendy W. L. Chan, Tsz Him So, Dora L. W. Kwong. Esophageal Squamous Cell Carcinoma. Methods in Molecular Biology 2020; 2129: 321 doi: 10.1007/978-1-0716-0377-2_24
|
4 |
Adam N. Bennett, Rui Xuan Huang, Qian He, Nikki P. Lee, Wing-Kin Sung, Kei Hang Katie Chan. Drug repositioning for esophageal squamous cell carcinoma. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.991842
|
5 |
Baoqing Chen, Shurui Liu, Lu Gan, Jingwen Wang, Binbin Hu, He Xu, Ruizhan Tong, Hui Yang, Ivan Cristina, Jianxin Xue, Xun Hu, You Lu. FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients. Cancer Biology & Therapy 2018; 19(1): 76 doi: 10.1080/15384047.2017.1394541
|